Warning: The NCBI web site requires JavaScript to function. more...
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F.
Breast Cancer Res. 2009;11(3):R40. Epub 2009 Jun 23.
Related citations
Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.
J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.
Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S.
Mod Pathol. 2010 Feb;23(2):270-5. Epub 2009 Nov 27.
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO.
Eur J Cancer. 2008 Jul;44(11):1541-51. Epub 2008 Jun 4.
GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D, Cheang M, Nielsen T.
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73.
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H.
Cancer Res. 2010 Jan 15;70(2):685-96. Epub 2010 Jan 12.
Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H.
Oncol Rep. 2010 Nov;24(5):1233-9.
Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J.
Eur J Clin Invest. 2008 Jun;38(6):438-46. Epub 2008 Apr 30.
GATA-3 expression as a predictor of hormone response in breast cancer.
Parikh P, Palazzo JP, Rose LJ, Daskalakis C, Weigel RJ.
J Am Coll Surg. 2005 May;200(5):705-10.
c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.
Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.
Tumori. 2006 Jul-Aug;92(4):311-7.
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.
Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.
Prognostic markers in triple-negative breast cancer.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.
Cancer. 2007 Jan 1;109(1):25-32.
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
Cancer Invest. 2008 Aug;26(7):671-9.
[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
Liu N, Niu Y, Wang SL, Yu Q, Zhang RJ, Liu TJ.
Zhonghua Yi Xue Za Zhi. 2010 May 25;90(20):1403-7. Chinese.
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.
BMC Cancer. 2011 Jul 15;11:299.
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.
Clin Cancer Res. 2004 Nov 15;10(22):7621-8.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.
J Natl Cancer Inst. 2009 May 20;101(10):736-50. Epub 2009 May 12.
FOXA1 as a therapeutic target for breast cancer.
Nakshatri H, Badve S.
Expert Opin Ther Targets. 2007 Apr;11(4):507-14. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on